Research out of Brigham and Women’s Hospital in Boston found heart failure patients who self-identify as black, Latinx or female are less likely to be admitted to the hospital’s cardiology department, suggesting admission bias might be a partial contributor to known racial disparities in HF outcomes.

The combo drug sacubitril/valsartan was associated with early improvements in health status in a study of nearly 4,000 patients with HFrEF.

Most patients on DOACs supplement their regimen with over-the-counter products, and one-third take at least one additional product that directly interferes with their blood thinners, according to work published in the Journal of the American Geriatrics Society.

Metformin use is linked to a lower risk of hospitalization for heart failure in patients with type 2 diabetes, a paper in the Journal of the American Heart Association confirms.

Apple has hired another big name in cardiology, signaling that it’s getting serious about its heart health initiatives, CNBC first reported Oct. 30.

Medicine is, and has been for years now, trending toward a more value-based payment system. But what exactly does that mean, and where does cardiology fit in?

California-based tech company HeartVista announced Oct. 29 it had received FDA clearance for its AI-assisted One Click cardiac MRI acquisition software.

A study of patients undergoing catheter ablation of atrial fibrillation between 2010 and 2015 found that early post-ablation mortality rates increased over the half-decade, reaching 1.35% per quarter by the end of the research period.

Finalized results from the OSLER-1 trial—the longest-running study of PCSK9 inhibitors to date—suggest evolocumab is safe and “consistently excellent” at lowering LDL-cholesterol through five years.

The notion of a digital transformation in cardiology, and healthcare as a whole, is an appealing one. But data presented at MedAxiom’s CV Transforum last week suggests we’re further away from a transformation than we might think.